Progress in the clinical application and correlation between glucose transporter-1 and
10.7507/1001-5515.202010004
- Author:
Manli YANG
1
;
Jinhui YOU
1
Author Information
1. Department of Nuclear Medicine, the Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R.China.
- Publication Type:Journal Article
- Keywords:
18F-fluorodeoxyglucose;
glucose metabolism;
glucose transporter-1;
non-small cell lung cancer;
positron emission tomography/computed tomography
- MeSH:
Carcinoma, Non-Small-Cell Lung/diagnostic imaging*;
Fluorodeoxyglucose F18;
Glucose Transport Proteins, Facilitative;
Glucose Transporter Type 1;
Humans;
Lung Neoplasms/diagnostic imaging*;
Positron Emission Tomography Computed Tomography;
Positron-Emission Tomography;
Radiopharmaceuticals
- From:
Journal of Biomedical Engineering
2021;38(2):399-404
- CountryChina
- Language:Chinese
-
Abstract:
Because of the unobvious early symptoms and low 5-year survival rate, the early diagnosis and treatment is of great significance for patients with non-small cell lung cancer. Glucose transporter-1 is the most widely distributed glucose transporters in various tissue cells in the human body, whose expression in non-small cell lung cancer is closely related to the histological types, lymph node metastasis, degree of differentiation, progression and prognosis.
